Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00871013 · ClinicalTrials.gov registry record · Phase 2
Trial for Patients Not Qualifying for TT4 and TT5 Protocols Because of Prior Therapy
A Phase 2 study of Myeloma, sponsored by University of Arkansas.
- Active
- Registry status
- Phase 2
- Development phase
- 160
- Enrollment target
- 1
- Study location
NCT00871013: Active Phase 2 study of Myeloma, sponsored by University of Arkansas.
NCT00871013 is a Phase 2 study of Myeloma that is active but no longer recruiting, run by University of Arkansas. The registered enrollment target is 160 participants, above the 94-participant average among 29 other Myeloma trials with a reported enrollment target (70% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00871013, a Phase 2 study of Myeloma, is active but no longer recruiting, sponsored by University of Arkansas.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 160 participants
- Enrollment target
- 1
- Study location
Study Summary
There have been four previous Total Therapy (TT1 through IIIB) studies for multiple myeloma at the MIRT from 1989 to present. Results have shown that participants treated on these studies had better outcomes (meaning they have lived longer and had better responses to treatment) when compared to individuals treated with standard chemotherapy. Past studies conducted at the MIRT have shown that participants presenting to MIRT who have already received treatment for myeloma tend to have shorter remissions (disappearance of signs and symptoms of myeloma) and do not survive as long as participants who come to MIRT with untreated myeloma. Researchers at MIRT think that one reason for this is may be that the myeloma cells re-grow in the time when participants are not receiving treatment because they are recovering from high-dose chemotherapy. In this study, participants will receive several chemotherapy drugs previously shown to be effective in myeloma, but in lower doses and in shorter cycles. It is hoped that by giving the drugs in this way, myeloma cells will not have time to re-grow between cycles, therefore resulting in longer remissions. This study is being done in an attempt to improve the remission rate and the survival time for participants with high-risk myeloma.
Conditions Studied
Interventions
- DRUG Melphalan
- DRUG Cisplatin
- DRUG Dexamethasone
- DRUG Thalidomide
- DRUG Velcade
Study Locations (1)
Arkansas
- University of Arkansas for Medical Sciences - Little Rock
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 160 participants |
| Start Date | 2009-03 |
| Est. Completion | 2026-12 |
| Phase | Phase 2 |
What the registry record for NCT00871013 still lists
NCT00871013 is an interventional study that assigns participants to a tested intervention. The registered 160 participants enrollment target is mid-sized for trials with a published cap, above the 94-participant average among 29 other Myeloma trials with a reported enrollment target (70% higher).
The record links to 1 condition, with Myeloma appearing as the primary indexed condition, and to 5 interventions - of which Melphalan is the first listed.
NCT00871013 reports a single indexed study location in Arkansas.
Frequently Asked Questions
What is clinical trial NCT00871013 about?
NCT00871013 is a clinical study titled "Trial for Patients Not Qualifying for TT4 and TT5 Protocols Because of Prior Therapy". There have been four previous Total Therapy (TT1 through IIIB) studies for multiple myeloma at the MIRT from 1989 to present. Results have shown that participants treated on these studies had better outcomes (meaning they have lived longer and had better responses to treatment) when compared to indi...
What is the current status of trial NCT00871013?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 160 participants. The study started on 2009-03. Estimated completion is 2026-12.
What conditions does trial NCT00871013 study?
This clinical trial studies the following conditions: Myeloma.
What interventions are being tested in trial NCT00871013?
The interventions under investigation include: Melphalan (DRUG), Cisplatin (DRUG), Dexamethasone (DRUG), Thalidomide (DRUG), Velcade (DRUG).
Who is sponsoring clinical trial NCT00871013?
This trial is sponsored by University of Arkansas, which has 318 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00871013 being conducted?
This trial has 1 study location across Arkansas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Myeloma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00871013's enrollment target sits among peer trials
160 5th of 29 higher than 25 of 29 other Myeloma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Myeloma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Elranatamab Post Cilta-cel in Patients With Clinical High Risk Relapsed Myeloma
RECRUITING · Phase 2
-
Study of Belantamab Mafodotin as Pre- and Post-autologous Stem Cell Transplant and Maintenance for Multiple Myeloma
ACTIVE NOT RECRUITING · Phase 2
-
Daratumumab, Carfilzomib, Lenalidomide and Low Dose Dexamethasone (DKRd) in Newly Diagnosed, Multiple Myeloma
ACTIVE NOT RECRUITING · Phase 2
-
Allo Non-myeloablative SCT Utilizing Matched Family Member Stem Cells Purged Using Campath
COMPLETED · Phase 2
-
Allo Non-Myeloablative SCT Utilizing Mis-Matched Family Member Stem Cells Purged Using Campath
COMPLETED · Phase 2
-
Efficacy Study of T Cell Depleted Allogeneic Non-myeloablative Stem Cell Transplant
COMPLETED · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00501826 · 160 participants · Phase 2
Combination Chemotherapy and Nelarabine in Treating Patients With T-cell Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma
- NCT00932139 · 160 participants · NA
Effect of Electro-Acupuncture on Blood Pressure
- NCT00992901 · 160 participants · Early Phase 1
Role of Neural and Hormonal Regulation Factors on Insulin Secretion After Gastric Bypass Surgery
- NCT01515527 · 160 participants · Phase 2
Cladribine Plus Low Dose Cytarabine (LDAC) Alternating With Decitabine in Patients With Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndrome (MDS)
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia